Equities research analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings of ($0.61) per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Intellia Therapeutics’ earnings, with estimates ranging from ($0.70) to ($0.56). Intellia Therapeutics posted earnings of ($0.53) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 15.1%. The firm is expected to issue its next quarterly earnings report on Wednesday, October 30th.

On average, analysts expect that Intellia Therapeutics will report full year earnings of ($2.29) per share for the current fiscal year, with EPS estimates ranging from ($2.48) to ($2.13). For the next financial year, analysts anticipate that the company will post earnings of ($2.69) per share, with EPS estimates ranging from ($3.49) to ($1.97). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.05. Intellia Therapeutics had a negative net margin of 242.65% and a negative return on equity of 33.03%. The company had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $7.15 million. During the same quarter in the prior year, the company posted ($0.52) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 44.2% compared to the same quarter last year.

NTLA has been the subject of a number of research analyst reports. Wedbush raised shares of Intellia Therapeutics from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $20.00 to $21.00 in a report on Friday, May 3rd. BidaskClub raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 20th. Chardan Capital reaffirmed a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a report on Tuesday, May 28th. Roth Capital initiated coverage on shares of Intellia Therapeutics in a report on Monday, June 10th. They issued a “neutral” rating and a $16.00 price target for the company. Finally, Robert W. Baird initiated coverage on shares of Intellia Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $23.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Intellia Therapeutics presently has an average rating of “Buy” and an average target price of $25.56.

Shares of NASDAQ NTLA traded up $0.12 during midday trading on Thursday, reaching $17.48. The company had a trading volume of 249,449 shares, compared to its average volume of 580,991. The company’s 50-day moving average is $16.94. The company has a market cap of $852.85 million, a PE ratio of -8.83 and a beta of 2.62. Intellia Therapeutics has a 1 year low of $11.03 and a 1 year high of $32.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.99 and a current ratio of 7.99.

Several large investors have recently added to or reduced their stakes in NTLA. Benjamin Edwards Inc. increased its stake in shares of Intellia Therapeutics by 60.9% in the second quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after acquiring an additional 640 shares during the period. Tortoise Investment Management LLC increased its stake in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock worth $34,000 after acquiring an additional 1,000 shares during the period. Quantamental Technologies LLC increased its stake in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock worth $56,000 after acquiring an additional 3,043 shares during the period. Bank of Montreal Can increased its stake in shares of Intellia Therapeutics by 406.5% in the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after acquiring an additional 3,069 shares during the period. Finally, Mizuho Securities Co. Ltd. acquired a new stake in shares of Intellia Therapeutics in the second quarter worth $64,000. Hedge funds and other institutional investors own 81.63% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

Featured Story: What are defining characteristics of a correction?

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.